ALBO News and Press, Albireo Pharma Inc. From 06/24/21

BOSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present as part of a fireside chat at Piper Sandler’s V...

Albireo Pharma (ALBO) presents new data showing efficacy and tolerability of Bylvay (odevixibat), as well as advancement in the characterization of A3907 in adult liver disease at EASL International Liver Congress 2021 on June 23 – 26.Highlights from the Phase 3 PEDFIC studies show fur...

– Bylvay demonstrates rapid reductions in serum bile acids and long-term improvements in growth, sleep, and hepatic parameters – – Bylvay patient responder data show sustained improvements in cholestasis markers vs. non-responders – – A...

– Phase 3 data presentations on long-term treatment and substantial clinical benefits of Bylvay™ (odevixibat) – – Data presentations on Phase 1 product candidate, A3907, in development for adult cholestatic liver disease – BOSTON, J...

Albireo Pharma (ALBO) announces data from its late-stage PEDFIC 1 trial and long-term extension study of its lead product candidate Bylvay (odevixibat) in patients with progressive familial intrahepatic cholestasis ((PFIC)), a disorder that causes progressive liver disease.Bylv...

– Data being presented show long-term benefits of Bylvay in children with PFIC – – First potential non-invasive treatment option that could transform the treatment paradigm – – Observed long-term improvements in total bilirubin, growth,...

Mirum aims to be a leader in the treatment of rare liver diseases for which the unmet medical need is high. Mirum is developing Maralixibat - a product as a pipeline - as a life-saving therapy for multiple ultra-rare pediatric liver disease indications with a market potential in the b...

BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present as part of fireside chats at both the 2021 Jefferi...

Albireo Pharma (ALBO) announces that the EMA's Committee for Medicinal Products for Human Use ((CHMP)) has issued a positive opinion recommending approval of Bylvay (odevixibat) for the treatment of Progressive familial intrahepatic cholestasis ((PFIC)).PFIC is a rare and devastating dis...

– Bylvay has the potential to become first approved drug to treat all forms of PFIC – – CHMP opinion is based on the PEDFIC Phase 3 studies – – PEDFIC 1 met the bile acid (P=0.003) and pruritus (P=0.004) primary endpoints, with a diarrh...